Table 1.
Clinical trials combining BiTEs and CPIs. mAb: monoclonal antibody; B-ALL: B-cell acute lymphoblastic leukaemia; B-LLy B-lymphoblastic lymphoma; r/r relapsed or refractory; MRD: minimal residual disease; PRAME: preferentially expressed antigen of melanoma; ImmTAC: immune mobilizing monoclonal T-cell receptors against cancer.
| BiTE | CPI | Phase | Study population | Identifier |
|---|---|---|---|---|
| Blinatumomab | AMG404 (anti-PD-1 mAb) | Ib | r/r B-ALL | NCT04524455 |
| Blinatumomab alone v Blinatumomab + Nivolumab | Nivolumab | II | First relapse B-ALL in paediatric and young adult patients | NCT04546399 |
| Blinatumomab | Pembrolizumab | I/II | r/r B-ALL with high bone marrow lymphoblast percentage | NCT03160079 |
| Blinatumomab | Pembrolizumab | I | r/r B-ALL in paediatric and young adult patients | NCT03605589 |
| Blinatumomab | Pembrolizumab | Ib | r/r Diffuse large B-cell lymphoma | NCT03340766 |
| Blinatumomab | Pembrolizumab | I/II | r/r B-ALL | NCT03512405 |
| Cibisatamab (CD3xCEA; RO6958688) | Atezolizumab | I | Metastatic colorectal cancer | NCT02650713 |
| MGD007 (CD3xgpA33) | MGA012 (anti-PD-1 mAb) | Ib/II | Metastatic colorectal cancer | NCT03531632 |
| Acapatamab (CD3xPSMA) | Pembrolizumab | I | Metastatic castration-resistant prostate cancer | NCT03792841 |
| REGN5678 (CD28xPSMA) | Cemiplimab (anti-PD-1 mAb) | I/II | Metastatic castration-resistant prostate cancer | NCT03972657 |
| REGN7075 (CD28xEGFR) | Cemiplimab | I/II | Advanced solid tumours | NCT04626635 |
|
REGN4018
(CD3xMUC16) |
Cemiplimab | I/II | Recurrent ovarian cancer | NCT03564340 |
|
REGN5668
(CD28xMUC16) |
Cemiplimab | I/II | Recurrent ovarian cancer | NCT04590326 |
|
Tebentafusp
(CD3xgp100 ImmTAC) |
Durvalumab (anti PD-L1)
Tremelimuumab (anti-CTLA-4) |
Ib/II | Advanced cutaneous melanoma | NCT02535078 |
|
IMC-F106
(CD3xPRAME ImmTAC) |
Atezolizumab
Pembrolizumab |
I/II | Advanced PRAME-positive cancers | NCT04262466 |